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Abstract
Purpose Currently, the most commonly used chelator for labelling antibodies with 89Zr for immunoPET is desferrioxamine B (DFO).
However, preclinical studies have shown that the limited in vivo stability of the 89Zr-DFO complex results in release of 89Zr, which
accumulates in mineral bone. Here we report a novel chelator DFOcyclo*, a preorganized extended DFO derivative that enables
octacoordination of the 89Zr radiometal. The aim was to compare the in vitro and in vivo stability of [89Zr]Zr-DFOcyclo*, [89Zr]Zr-
DFO* and [89Zr]Zr-DFO.
Methods The stability of 89Zr-labelled chelators alone and after conjugation to trastuzumabwas evaluated in human plasma and PBS,
and in the presence of excess EDTA or DFO. The immunoreactive fraction, IC50, and internalization rate of the conjugates were
evaluated using HER2-expressing SKOV-3 cells. The in vivo distribution was investigated in mice with subcutaneous HER2+ SKOV-
3 or HER2− MDA-MB-231 xenografts by PET/CT imaging and quantitative ex vivo tissue analyses 7 days after injection.
Results 89Zr-labelled DFO, DFO* and DFOcyclo* were stable in human plasma for up to 7 days. In competition with EDTA, DFO*
and DFOcyclo* showed higher stability than DFO. In competition with excess DFO, DFOcyclo*-trastuzumabwas significantly more
stable than the corresponding DFO and DFO* conjugates (p < 0.001). Cell binding and internalization were similar for the three
conjugates. In in vivo studies, HER2+ SKOV-3 tumour-bearing mice showed significantly lower bone uptake (p < 0.001) 168 h after
injection with [89Zr]Zr-DFOcyclo*-trastuzumab (femur 1.5 ± 0.3%ID/g, knee 2.1 ± 0.4%ID/g) or [89Zr]Zr-DFO*-trastuzumab (femur
2.0 ± 0.3%ID/g, knee 2.68 ± 0.4%ID/g) than after injection with [89Zr]Zr-DFO-trastuzumab (femur 4.5 ± 0.6%ID/g, knee 7.8 ±
0.6%ID/g). Blood levels, tumour uptake and uptake in other organs were not significantly different at 168 h after injection. HER2−
MDA-MB-231 tumour-bearing mice showed significantly lower tumour uptake (p < 0.001) after injection with [89Zr]Zr-DFOcyclo*-
trastuzumab (16.2 ± 10.1%ID/g) and [89Zr]Zr-DFO-trastuzumab (19.6 ± 3.2%ID/g) than HER2+ SKOV-3 tumour-bearingmice (72.1
± 14.6%ID/g and 93.1 ± 20.9%ID/g, respectively), while bone uptake was similar.
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Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00259-019-04343-2) contains supplementary
material, which is available to authorized users.
* Jean-Claude Chambron
jcchambron@unistra.fr
* Sandra Heskamp
Sandra.heskamp@radboudumc.nl
* Franck Denat
franck.denat@u-bourgogne.fr
1 Department of Radiology and Nuclear Medicine, Radboudumc,
Radboud Institute for Molecular Life Sciences,
Nijmegen, The Netherlands
2 Institut de Chimie Moléculaire de l’Université de Bourgogne, UMR
6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A.
Savary, 21078 Dijon Cedex, France
3 Global Research Technologies, Novo Nordisk A/S, Novo Nordisk
Park, DK-2760 Måløv, Denmark
4 Institut de Chimie de Strasbourg, UMR 7177, CNRS, Université de
Strasbourg, 1 rue Blaise Pascal, 67008 Strasbourg Cedex, France
European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:1966–1977
https://doi.org/10.1007/s00259-019-04343-2
# The Author(s) 2019
Conclusion 89Zr-labelled DFOcyclo* and DFOcyclo*-trastuzumab showed higher in vitro and in vivo stability than the current
commonly used 89Zr-DFO-trastuzumab. DFOcyclo* is a promising candidate to become the new clinically used standard chelator
for 89Zr immunoPET.
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Introduction
89Zr has shown great potential as a radionuclide for immunoPET
imaging with monoclonal antibodies. 89Zr has favourable char-
acteristics: its half-life of 78.4 h matches the kinetics of IgG
molecules, it is a residualizing radionuclide that provides images
with high target to background ratios [1], and high PET image
resolution is obtained because of the relatively low-energy posi-
trons (Emean = 395 keV), which is not affected by its γ-emission
at 909 keV. Because of these advantages it is frequently used in
preference to other long-lived positron emitters, such as 124I.
Despite these favourable characteristics for immunoPET, the
use of 89Zr has a major drawback when used in combination
with the clinically approved chelator currently used for antibody
labelling, desferrioxamine B (DFO). In vivo studies have re-
vealed that a fraction of 89Zr is released from DFO, resulting in
accumulation of 89Zr in mineral bone [2–6]. This may hamper
the detection of bone metastases, an undesired radiation dose to
bone marrow, and overestimation of the radiation dose to the red
marrow in radionuclide therapy dose planning. Release of 89Zr
from DFO is the result of suboptimal complexation. 89Zr4+ de-
mands octacoordination to form stable complexes, while the
three hydroxamate groups of DFO only offer hexacoordination,
resulting in additional binding of water molecules to saturate the
coordination sphere of 89Zr4+ [5]. Eventually this can result in the
release of 89Zr, which may subsequently accumulate in mineral
bone [5, 7].
To overcome the limited stability of the [89Zr]Zr-DFO com-
plex, alternative chelators for [89Zr]Zr4+ have been developed
[8–10]. Examples are DFO derivatives such as DFO* [11] and
other Bextended^DFO analogues [12], or DFO squaramide ester
[13]. Macrocyclic compounds with three or four hydroxamic
acid groups [14–16], and chelating agents based on
hydroxypyridinone, terephthalamide or catecholate groups as
alternatives to hydroxamate-based chelators have also been eval-
uated [17–24]. Furthermore, the well-known chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (H4DOTA) has
also been found to chelate [89Zr]Zr4+ very efficiently. However,
in the absence of an improved, clinically applicable chelator,
there is room for more efficient [89Zr]Zr4+ chelators.
In a quest for a more stable Zr4+ chelate, we have developed a
new bifunctional DFO derivative, DFOcyclo*-pPhe-NCS. By
addition of a fourth hydroxamic acid cyclic group, an octadentate
DFO derivative with the expected Zr4+ coordination properties
was synthesized. The in vitro stability of radiolabelled
DFOcyclo* was compared with that of radiolabelled DFO and
DFO*. Subsequently, all three chelators were conjugated to
trastuzumab (Herceptin) by random isothiocyanate-based conju-
gation, and the in vivo stability of the conjugates was evaluated
in tumour-bearing nude mice. Finally, in an attempt to elucidate
the mechanism of 89Zr release from DFO, the hypothesis that
89Zr is released from its chelate upon internalization by cancer
cells was tested using a HER2-negative tumour model.
Materials and methods
Reagents and equipment specifications
All chemicals, unless otherwise noted, were purchased from
Sigma-Aldrich, and used as received without further purifica-
tion. Ultrapure water produced by a PURELAB Ultra system
from ELGAwas used throughout (18.2 MΩ cm). NMR spectra
were acquired on a Bruker Avance III HD spectrometer oper-
ating at 600MHz. The conjugates were purified by FPLC on an
Äkta Pure 25 M chromatography system (GE Healthcare Life
Sciences). MALDI-TOF mass spectra were acquired on an
ultrafleXtreme instrument (Bruker Daltonics). Size-exclusion
chromatography (SEC-HPLC) analyses were performed on a
JASCOHPLC system LC-2000 analytical series equippedwith
a Superdex 200 5/150 GL column. Instant thin-layer chroma-
tography (iTLC) was performed using sheets impregnated with
salicylic acid (iTLC-SA; Agilent) eluted with 0.1 M EDTA,
pH 5.0, and analysed on an AR-2000 radio-TLC plate reader
(Bioscan Inc.). PET/CT scans were acquired on an Inveon an-
imal PET scanner (Siemens Preclinical Solutions).
Synthesis of chelators
DFO-pPhe-NCS was provided by Chematech. DFO* was
synthesized according to a previously described procedure
[25], with slight modifications enabling isolation of the de-
sired compound in good yield without the need for cumber-
some purifications. Likewise, the preparation of DFO*-pPhe-
NCSwas adapted from a previously described procedure [25].
DFOcyclo*-pPhe-NCSwill soon become commercially avail-
able, but in the meantime samples can be obtained from the
authors upon request. Briefly, DFOcyclo*-pPhe-NCS was ob-
tained by hemisynthesis in three steps from commercially ob-
tained Desferal and a functionalized 1-hydroxypiperidine-2-
one (1,2-PIPOH) derivative [26]. After benzyl deprotection
under H2 on Pd/C, the functionalized tetrachelate was reacted
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in a final step with a large excess of p-phenylene
diisothiocyanate (PDITC), and the reaction was stopped at
an early stage to favour single condensation. DFOcyclo*-
pPhe-NCS was obtained in 14% isolated yield after direct
injection of the crude reaction mixture onto a semipreparative
HPLC column and elution with water/acetonitrile/formic acid
with a gradient of 70:30:0.1 to 30:70:0.1. The compound was
fully characterized and identified by 1H NMR spectroscopy
(Supplementary Figs. 1–3), HR-ESI-MS (Supplementary
Figs. 4–6), and analytical HPLC (Supplementary Fig. 6).
89Zr radiolabelling of chelates
To 25 μL 1 M HEPES (pH 7.4) was added 2.5 μL of a 1 mM
solution of chelator in water. To this solution was added
5 MBq of [89Zr][Zr(oxalate)4]
4− adjusted to pH 7.4 with 2 M
Na2CO3. The mixture was incubated at room temperature for
15 min. The progress of the reaction was then assayed using
iTLC, and complete chelation was observed.
Stability of the chelates in human plasma and EDTA
challenge
The radiochemical purity and the stability of the 89Zr-labelled
chelates was assessed in plasma and in the presence of EDTA,
either by adding 1.5 MBq of radiolabelled chelate to 200 μL
of human plasma or by adding 1,000 equivalents of EDTA to
1MBq of the radiolabelled chelate diluted to 50 μL with PBS.
The mixtures were incubated at 37 °C. Aliquots were analysed
by iTLC-SA after 24, 48, 72, 96 and 168 h. All samples were
prepared in triplicate.
Determination of the partition coefficient
of the radiolabelled chelates
The log D values of the radiolabelled chelates (in their –NH2
version) were determined using an n-octanol/PBS (pH 7.4) sys-
tem. The radiolabelled chelate (10 μL, 0.5 MBq) was added to
1 mL of PBS, pH 7.4. This solution was supplemented with
1 mL of n-octanol previously saturated with water. The mixture
was vigorously stirred for 20 min at 25 °C. The two layers were
then separated by centrifugation and 50 μL of each layer was
collected and counted in an automatic Wizard γ-counter
(PerkinElmer). All samples were measured in triplicate. The
partition coefficient D was calculated using the following for-
mula: log D = log (Aoct/APBS), where Aoct and APBS are the
activity of the n-octanol and PBS layer, respectively.
Trastuzumab conjugation
Bifunctional chelator (30 equivalents, 51.5μLof a 20mMstock
solution inDMSO)was added to 5.0mg of purified trastuzumab
(in solution at 4 mg/mL in 0.2 M sodium bicarbonate buffer
(pH 8.4 buffer for DFO-pPhe-NCS and DFOcyclo*-pPhe-
NCS conjugation) and 0.1 M borate buffer (pH 9.5 buffer for
DFO*-pPhe-NCS conjugation; Fig. 1). The reaction mixture
was stirred at 900 rpm overnight at 37 °C. The mixture was
purified by FPLC. Excess chelator was washed awaywith phos-
phate buffer (20 mM, pH 7.3) and the conjugate was eluted with
50 mM acetate buffer (pH 3.0), and subsequently the buffer was
changed to PBS, pH 7.4, in an ultracentrifugal filter device
(Amicon Ultra 2 mL, Ultracel cut-off 30 kDa; Merck
Millipore). The protein recovery rate was >89%.
89Zr radiolabelling of conjugates
To 100 μL of 1 M HEPES, pH 7.3, were added 500 μg of
trastuzumab conjugate in PBS, pH 7.4. To this solution
were added 25 MBq of a [89Zr][Zr(oxalate)4]
4− solution ad-
justed to pH 7.4 with 2 M Na2CO3. The mixture was incubat-
ed at room temperature for 30 min. The progress of the reac-
tion was assayed using iTLC, and complete chelation was
observed. The radiolabelled conjugate was purified and con-
centrated using centrifugal filtration units with a 30 kDa mo-
lecular weight cut-off filter (Amicon Ultra 0.5 mL; Centrifugal
Filtration Units, Merck Millipore). Prior to in vivo injection,
89Zr-labelled trastuzumab conjugates were purified by elution
on prewashed PD-10 desalting columns (GE Healthcare Life
Sciences) eluted with PBS (pH 7.4), instead of purification
and concentration using centrifugal filtration units.
Stability studies of conjugates
EDTA challenge of the radiolabelled conjugates
The stability of the conjugates in the presence of EDTA was
assessed by adding 1,000 equivalents of EDTA to 0.3–
0.5 MBq of the conjugate and diluting the mixture to 50 μL
with PBS. The mixture was incubated at 37 °C. Aliquots were
analysed by iTLC-SA after 24, 48, 72, 96 and 168 h. All
samples were prepared in triplicate.
DFO challenge of the radiolabelled conjugates
To assess the stability of the conjugates in the presence of
DFO, 2–2.5 MBq of the conjugate was supplemented with
1,000 equivalents of DFO and diluted to 50 μL with PBS.
The mixture was incubated at 37 °C. Aliquots were analysed
by size-exclusion chromatography after 1, 4, 8, 12, 24 and
48 h. All samples were prepared in triplicate.
Cell culture
The HER2+ human ovarian cancer cell line SKOV-3 (HTB-77;
ATCC) and the HER2− human breast cancer cell line MDA-
MB-231 (HTB-26; ATCC) were cultured in RPMI-1640
1968 Eur J Nucl Med Mol Imaging (2019) 46:1966–1977
medium (Gibco, ThermoFisher Scientific, Waltham, MA,
USA) supplemented with 2 mM glutamine (Gibco) and 10%
fetal calf serum (Sigma-Aldrich Chemie BV), at 37 °C in a
humidified atmosphere containing 5% CO2. Cells were disso-
ciated when 80–90% confluency was reached using 0.05%
trypsin (w/v) in 0.53mMEDTA (Life Technologies) and main-
tained as proliferating cultures. Mycoplasma contamination
was evaluated every 4 months using a MycoAlert mycoplasma
detection kit (Lonza, Basel, Switzerland). After thawing, cells
were maintained in culture for a maximum of 6 months.
Binding and internalization assay
The binding and internalization kinetics of trastuzumab con-
jugated with DFO, DFO* and DFOcyclo* labelled with 89Zr
were tested using SKOV-3 cells and MDA-MB-231 cells.
Cells (0.5 × 106 cells/well) were cultured in six-well plates
and incubated with 250 pM 89Zr-labelled DFO-trastuzumab,
DFO*-trastuzumab or DFOcyclo*-trastuzumab in 0.5%BSA/
RPMI-1640 medium (w/v) for 1, 4 and 24 h. Nonspecific
binding and internalization was determined by coincubation
with 500 nM unlabelled trastuzumab. The membrane-bound
fraction was removed from the cells by incubation in an ice-
cold solution containing 0.1 M acetic acid and 154 mMNaCl,
pH 2.6, for 10 min. Cells were harvested by incubation in
0.1 M NaOH for 5 min. Binding and internalization were
determined by counting the radioactivity using a gamma
counter (Wizard, PerkinElmer).
Immunoreactive fraction
The immunoreactive fraction of 89Zr-labelled trastuzumab
was determined as described by Lindmo et al. [27]. In brief,
a serial dilution of SKOV-3 cells ranging from 2.5 × 106 to
1.56 × 105 cells in 0.5 ml were incubated with 250 pM 89Zr-
labelled DFO-trastuzumab, DFO*-trastuzumab, or
DFOcyclo*-trastuzumab at 37 °C for 30 min. Nonspecific
binding was determined by incubation of 1.56 × 106 cells with
an excess of nonlabelled trastuzumab (500 nM). After incu-
bation, cells were washed twice and the radioactivity in the
cell pellet was measured using a gamma counter (Wizard,
PerkinElmer).
In vivo stability studies
Animals
The Dutch Central Committee on Animal Research and the
local Ethics Committee on Animal Research of Radboud
University approved this study under protocol 2015-0071.
All animal experiments were performed according to institu-
tional guidelines. Upon arrival, female BALB/cAnNRj-
Foxn1nu/Foxn1nu mice at 6–8 weeks of age (Janvier Labs,
France) were randomly tattooed for identification and were
acclimatized for ≥4 days before any experimental procedure.
Mice had unlimited access to food and water and were main-
tained with five or six mice per cage in a controlled environ-
ment (22 ± 1 °C, 55 ± 10% humidity, 12-h dark/light cycle).
Cages were replaced weekly with clean cages. Mice were
assessed daily for welfare and tumour sizes were measured
twice a week after tumour inoculation. Mice were randomly
allocated to the experimental groups according to a random
sequence generator and the biotechnicians performing the ex-
periments were blinded to the group allocation. Tumours were
inoculated by subcutaneous (s.c.) injection of 5 × 106 SKOV-3
or MDA-MB-231 cells mixed 2:1 or 1:1 in Matrigel (BD
Biosciences; Pharmingen), respectively. Experiments were
started when tumours had reached a size of 0.4–0.5 mm3.
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Fig. 1 Molecular structures of the conjugates considered in this work: DFO-trastuzumab, DFO*-trastuzumab, and DFOcyclo*-trastuzumab
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In vivo stability studies
In a first experiment, the in vivo stability of [89Zr]Zr-
DFOcyclo*-trastuzumab was compared with that of
[89Zr]Zr-DFO-trastuzumab. SKOV-3 tumour-bearing mice
were injected with 200 μL (750 kBq) [89Zr]Zr-DFO-
trastuzumab and [89Zr]Zr-DFOcyclo*-trastuzumab, together
with 85 μg nonradiolabelled trastuzumab (Herceptin, Roche)
to a total of 100 μg trastuzumab. The ex vivo biodistribution
of the 89Zr-labelled conjugates was determined by killing the
mice by CO2/O2 asphyxiation at 24 h (five mice per group),
72 h (five mice) and 168 h (six mice) after injection, and
collecting tumour, blood, muscle, heart, lung, spleen, pancre-
as, kidney, liver, stomach, duodenum, colon, salivary glands,
sternum, femur, knee and bone marrow. To determine the
blood kinetics, blood samples were collected at 1, 3, 24, 72
and 168 h after injection via a tail vein (live mice) or by heart
puncture (killed mice). 89Zr radioactivity was quantified in the
collected samples using a gamma counter (Wizard,
PerkinElmer) and expressed as percentage of injected dose
per gram of tissue (%ID/g), calculated from the amount of
radioactivity measured in aliquots of the injected dose.
Simultaneously, mice bearing HER2− MDA-MB-231 s.c. tu-
mours (six mice per group) were also injected with 200 μL
(750 kBq) [89Zr]Zr-DFO-trastuzumab or [89Zr]Zr-
DFOcyclo*-trastuzumab to investigate whether [89Zr]Zr4+ is
released from its chelate upon HER2-mediated internalization
by cancer cells. Blood kinetics and ex vivo biodistribution
analyses were performed as described above.
In a second experiment, the in vivo stability of [89Zr]Zr-
DFO-trastuzumab and [89Zr]Zr-DFOcyclo*-trastuzumab was
compared with that of [89Zr]Zr-DFO*-trastuzumab, a promis-
ing recently described [89Zr]Zr4+ chelate [25]. SKOV-3 s.c.
tumour-bearing mice were injected with 200 μL (5 MBq)
[89Zr]Zr-DFO-trastuzumab (five mice per group), [89Zr]Zr-
DFOcyclo*-trastuzumab (six mice) and [89Zr]Zr-DFO*-
trastuzumab (six mice) together with 5, 11 and 10.3 μg of
nonradiolabelled trastuzumab to a total of 100 μg trastuzumab
for DFO-trastuzumab, DFOcyclo*-trastuzumab and DFO*-
trastuzumab, respectively. Two mice from each group were
randomly selected for PET imaging. Mice were imaged under
general anaesthesia (2–3% isoflurane/O2) for 20min at 24 and
72 h after injection. PETscans were followed by a CTscan for
anatomic reference (spatial resolution of 113 μm, 80 kV, and
500 μA). Scans were reconstructed using Inveon Acquisition
Workplace software with iterative three-dimensional ordered
subsets expectation maximization using a maximum a priori
algorithmwith shifted Poisson distribution, with the following
parameters: matrix 256 × 256 × 161, pixel size 0.4 × 0.4 ×
0.8 mm, with a corresponding beta of 0.05 mm. At 168 h after
injection, mice were killed and imaged for 30 min.
Subsequently, the biodistribution of the three 89Zr-labelled
conjugates was determined ex vivo as described before.
Blood kinetics were determined in live mice as described
above at 1, 3, 24 and 72 h after injection.
Statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 5.03 for Windows. Differences in 89Zr tissue uptake were
tested for significance using Student’s t-test or one-way
ANOVAwith a Bonferroni’s post-hoc test.
Results
Chelator structure
DFOcyclo* is an analogue of DFO*. Both chelators contain
four hydroxamate moieties, instead of only three for DFO.
The main difference between DFO* and DFOcyclo* is the
cyclic structure of the additional hydroxamic acid group de-
rived from 1,2-PIPOH. While open-chain hydroxamic acids,
including DFO, are known to exist as a mixture of two E
(trans) and Z (cis) isomers [28–30], the Z configuration of
the hydroxamate group is imparted by the cyclic structure of
PIPO-, and is obviously more favourable for Zr4+ coordination
and could therefore result in a more stable complex [31]. The
crystal structure of a Zr4+ complex in which the metal is co-
ordinated by four 1,2-PIPO- chelates has been reported previ-
ously [32].
The chemical structure of DFOcyclo*-pPhe-NCS, the im-
mediate precursor of the DFOcyclo*-trastuzumab bioconju-
gate, was established by NMR (Supplementary Figs. 1–3)
and HR-ESI-MS spectroscopy (Supplementary Figs. 4–5).
The 1H NMR spectrum in DMSO-d6 showed the characteristic
signals of DFO, the PIPOH additional chelate, and the
isothiocyanate-functionalized tether (Supplementary Fig. 1).
Noticeably, all the heteroatom-bound hydroxamic (H1, H15,
H26, H37), amide (H9, H20, H31) and thiourea (H44, H45)
protons could be located in the 1H NMR spectrum. The
hydroxamic protons and the thiourea proton H45 appeared as
broad singlets in the low-field region of the spectrum
(>9.5 ppm in DMSO-d6), while the aliphatic amide protons
appeared at 7.5–8 ppm as well-resolved triplets, together with
the doublets of the aromatic protons (H46, H47). As shown by
the ROESY map, the hydroxamic protons exchanged with wa-
ter protons, and showed multiple correlations with their neigh-
bours (Supplementary Fig. 2). This information was very valu-
able for the assignment of the signals of the aliphatic protons,
which showed multiple overlaps. In this way, aliphatic protons
of the PIPOH fragment (H4, H5, H6), of the DFO backbone
(H10–H14, H17, H18, H21–H25, H28, H29, H32–H36, H39),
and of the aliphatic tether (H7, H40–H43) could be assigned
without any ambiguity (Supplementary Fig. 3).
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Partition coefficient of the radiolabelled chelates
There was no significant difference in the octanol/water par-
tition coefficient between the [89Zr]Zr-DFO-NH2 and the
[89Zr]Zr-DFO*-NH2 chelates (log D −3.61 ± 0.21 and −3.54
± 0.16, respectively). However, DFOcyclo* exhibited a slight-
ly more lipophilic behaviour than DFO and DFO* (log D
−2.14 ± 0.10 for [89Zr]Zr-DFOcyclo*-NH2) due to the addi-
tion of the piperidine ring.
Conjugation trastuzumab substitution ratio
The degree of labelling of the conjugates DFO-trastuzumab,
DFOcyclo*-trastuzumab and DFO*-trastuzumab was deter-
mined by mass spectrometry. The values obtained ranged
from 2.6 to 4.7 for DFO-trastuzumab, and were 3.7 and 2.6
for DFOcyclo*-trastuzumab and DFO*-trastuzumab,
respectively.
Chelate/conjugate labelling, specific activity
and stability
The chelators were quantitatively labelled with specific activ-
ities reaching 4 MBq/nmol. All chelates remained stable in
plasma after 7 days (Fig. 2a). Importantly, [89Zr]Zr-DFO*
and [89Zr]Zr-DFOcyclo* showed higher stability than
[89Zr]Zr-DFO in the presence of excess EDTA. The integrity
of [89Zr]Zr-DFO decreased to 53%, while the [89Zr]Zr-DFO*
and [89Zr]Zr-DFOcyclo* complexes remained >98% intact
after 7 days (Fig. 2b).
The conjugates were quantitatively labelled at a specific
activity of 50 GBq/g (7.5 MBq/nmol). Size-exclusion chro-
matography revealed the presence of aggregates in small
Fig. 2 Stability of [89Zr]Zr-DFO (red), [89Zr]Zr-DFO* (green) and
[89Zr]Zr-DFOcyclo* (blue) in human plasma (a) and in the presence of
1,000 equivalents of EDTA (b) at 37 °C. Stability of [89Zr]Zr-DFO-
trastuzumab (red), [89Zr]Zr-DFO*-trastuzumab (green) and [89Zr]Zr-
DFOcyclo*-trastuzumab (blue) in the presence of 1,000 equivalents of
EDTA (c) and 1,000 equivalents of DFO (d) at 37 °C. Bound and
internalized conjugates in HER2+ SKOV-3 cells after 1, 4 and 24 h of
incubation (e). Error bars represent standard deviations. **p < 0.01,
***p < 0.001
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amounts for the three radioconjugates: 4.7 ± 0.3%, 3.6 ± 0.2%
and 6.5 ± 0.7% for [89Zr]Zr-DFOcyclo*-trastuzumab,
[89Zr]Zr-DFO-trastuzumab and [89Zr]Zr-DFO*-trastuzumab,
respectively. This aggregation was probably because of the
choice of the bioconjugation moiety, as phenyl-
isothiocyanate is known to cause aggregation [33, 34]. Like
the free chelates, the 89Zr-labelled DFO*- and DFOcyclo*-
based conjugates showed higher stability than the DFO-
based conjugate. The competition experiments with EDTA
gave results similar to those with the chelates alone (Fig.
2c). However, incubation of the radiolabelled conjugates with
DFO clearly discriminated the stability of the three conjugates
(Fig. 2d). While the integrity of [89Zr]Zr-DFO*-trastuzumab
decreased to 50% in 4 h, [89Zr]Zr-DFOcyclo*-trastuzumab
reached 50% of integrity in 48 h, and seemed to plateau
around 50% integrity, suggesting a much higher stability for
this radiolabelled conjugate. The DFO-based conjugate exhib-
ited the lowest stability, with an almost total release of radio-
nuclide in less than 10 h.
In vitro assays
The cell binding and internalization assay using HER2+
SKOV-3 cells showed 2–4% binding for the three conjugates
at 1 and 4 h, and approximately 4–5% at 24 h (Fig. 2e).
Internalization of the three conjugates in HER2+ SKOV-3
cells was about 12–14% at 1 h, and increased to approximate-
ly 30–40% at 4 and 24 h (Fig. 2e). Incubation with an excess
of nonradiolabelled trastuzumab or incubation with HER2−
MDA-MB-231 cells resulted in binding and internalization
of the three conjugates of <1% at all time points
(Supplementary Fig. 7). The immunoreactive fraction of all
three conjugates was >90%.
Pharmacokinetics and biodistribution
of the radiolabelled conjugates in HER2+
tumour-bearing mice
The in vivo charac te r i s t i cs o f [ 89Zr ]Zr-DFO-
trastuzumab and [89Zr]Zr-DFOcyclo*-trastuzumab were
determined by intravenous injection into HER2+
SKOV-3 s.c. tumour-bearing nude mice. Blood levels
determined at 1, 3, 24, 72 and 168 h after injection
showed similar patterns for both conjugates (Fig. 3a).
Tumour uptake increased from 26.2 ± 3.6%ID/g and
39.4 ± 12.7%ID/g at 24 h after injection to 93.1 ±
20.9%ID/g and 72.1 ± 14.6%ID/g at 168 h after injec-
tion for [89Zr]Zr-DFO-trastuzumab and [89Zr]Zr-
DFOcyclo*-trastuzumab, respectively, but was not sig-
nificantly different between the conjugates (Fig. 4a–c).
Bone uptake was significantly lower in mice injected
with [89Zr]Zr-DFOcyclo*-trastuzumab at 72 h after ad-
ministration (femur p < 0.05, knee p < 0.001; Fig. 4b).
At 168 h after injection, 89Zr uptake was significantly
lower in the sternum (p < 0.01), femur (p < 0.0001) and
knee (p < 0.0001) in mice injected with [89Zr]Zr-
DFOcyclo*-trastuzumab than in mice injected with
[89Zr]Zr-DFO-trastuzumab. Uptake in muscle and pan-
creas was significantly higher in mice injected with
89Zr-DFOcyclo*-trastuzumab at 24 h after injection
(p < 0.05), but was not different at 72 and 168 h after
injection (Fig. 4a–c). Uptake in other organs was not
significantly different for the two conjugates.
In vivo blood kinetics and biodistribution in HER2−
tumour-bearing mice
To investigate the hypothesis that 89Zr is released from the
chelator after cellular internalization, two groups of mice bear-
ing HER2− MDA-MB-231 s.c. tumours were injected with
750 kBq (100 μg) [89Zr]Zr-DFO-trastuzumab or [89Zr]Zr-
DFOcyclo*-trastuzumab. Blood levels determined at 1, 3,
24, 72 and 168 h after injection showed a pattern similar to
the kinetics in mice with HER2+ tumours (Fig. 3b). Ex vivo
biodistribution showed a significantly lower uptake in HER2−
tumours than in HER2+ tumours for both conjugates
(p < 0.001; Fig. 4c, d). 89Zr uptake in bone (sternum, femur
and knee) in HER2− tumour-bearing mice was comparable to
that in HER2+ tumour-bearing mice: in both groups bone
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Fig. 3 Blood kinetics of [89Zr]Zr-DFO-trastuzumab (red) and [89Zr]Zr-DFOcyclo*-trastuzumab (blue) in HER2+ SKOV-3 tumour-bearing mice (a) and
HER2− MDA-MB-231 tumour-bearing mice (b). Error bars represent standard deviations
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Fig. 4 Biodistribution of [89Zr]Zr-DFO-trastuzumab (white bars) and
[89Zr]Zr-DFOcyclo*-trastuzumab (grey bars) in HER2+ SKOV-3 tu-
mour-bearing mice (a–c) at 24 h (a), 72 h (b) and 168 h (c) after injection,
and in HER2− MDA-MB-231 tumour-bearing mice (d) at 168 h after
injection. Bars represent means with standard deviations. *p < 0.05,
**p < 0.01, ***p < 0.001
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uptake was significantly lower in mice injected with [89Zr]Zr-
DFOcyclo*-trastuzumab.
In vivo stability comparison to DFO*
In a final experiment, the in vivo stability of [89Zr]Zr-
DFO-trastuzumab and [89Zr]Zr-DFOcyclo*-trastuzumab
were compared with that of [89Zr]Zr-DFO*-trastuzumab.
Tumour uptakes were similar and not significantly dif-
ferent among the three conjugates (Fig. 5a). 89Zr uptake
in the femur and knee was significantly lower in mice
injected with [89Zr]Zr-DFOcyclo*-trastuzumab and
[89Zr]Zr-DFO*-trastuzumab than in mice injected with
[89Zr]Zr-DFO-trastuzumab (p < 0.0001). 89Zr uptake in
the sternum was significantly lower in mice injected
with [89Zr]Zr-DFOcyclo*-trastuzumab than in mice
injected with [89Zr]Zr-DFO-trastuzumab (p < 0.0001),
but not in mice injected wi th [89Zr]Zr-DFO*-
trastuzumab. Blood kinetics and uptake in all other tis-
sues were similar among the three conjugates (Fig. 5b).
Most importantly, PET images revealed bone uptake in
mice injected with [89Zr]Zr-DFO-trastuzumab, but not in
mice injected with [89Zr]Zr-DFOcyclo*-trastuzumab or
[89Zr]Zr-DFO*-trastuzumab at 168 h after injection
(Fig. 6).
Discussion
We report here a new 89Zr chelator, DFOcyclo*, with im-
proved in vitro and in vivo stability characteristics compared
with currently the most common chelator used clinically,
DFO. Because of the octacoordination obtained by the addi-
tion of a fourth cyclic hydroxamic acid group, DFOcyclo*
produced a more stable complex with [89Zr]Zr4+ than the
hexacoordinating chelator DFO. The results of competition
assays with excess EDTA and DFO emphasized the improved
stability of the complex indicated by easy 89Zr release from
DFO and DFO-trastuzumab, while it was significantly less
easily released from DFOcyclo* and DFOcyclo*-
trastuzumab. The results of in vivo studies confirmed these
findings, as indicated by significantly lower 89Zr uptake in
mineral bone following injection of 89Zr-DFOcyclo*-
trastuzumab. In a head-to-head comparison with DFO*, a re-
lated tetrahydroxamic DFO derivative with higher stability
than the parent DFO as described by Vugts et al. [25],
DFO* and DFOcyclo* showed similar in vitro and in vivo
stability characteristics. Only when challenged with an excess
of DFO in vitro (Fig. 2c) and in terms of sternum uptake
in vivo (Fig. 5a), did DFOcyclo* outperform DFO*, suggest-
ing that [89Zr]Zr-DFOcyclo* shows higher thermodynamic
stability than [89Zr]Zr-DFO*. This higher stability can most
likely be ascribed to the preorganization effect of the
Fig. 5 a Biodistribution of
[89Zr]Zr-DFO-trastuzumab (white
bars), [89Zr]Zr-DFOcyclo*-
trastuzumab (grey bars) and
[89Zr]Zr-DFO*-trastuzumab
(black bars) at 168 h after
injection and blood kinetics. b
Blood kinetics after injection in
HER2+ SKOV-3 tumour-bearing
mice. Bars represent means with
standard deviations. ***
p < 0.0001
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additional cyclic cis-hydroxamate binding unit found in
DFOcyclo* as compared with the open-chain chelating motifs
of DFO*.
In addition to DFO*, other chelating agents such as DFO
squaramide ester, hydroxamic acid-based macrocycles,
hydroxypyridinone (HOPO) derivatives, and DOTA have
been proposed as alternatives to DFO for labelling antibodies
with 89Zr. The DFO squaramide ester has the advantages of
being more soluble in water and causing less aggregation of
antibodies, and shows promising stability reflected by lower
in vivo 89Zr bone uptake at 24 h and 48 h after injection than
DFO [13]. However, at a later time point (96 h after injection),
the difference was not so pronounced, while in our study the
difference in 89Zr bone uptake between mice injected with
[89Zr]Zr-DFOcyclo*-trastuzumab and [89Zr]Zr-DFO-
trastuzumab increased over time, suggesting that [89Zr]Zr-
DFOcyclo* has higher in vivo stability than [89Zr]Zr-DFO
squaramide.
Besides DFO derivatives, macrocyclic chelators have also
been tested as 89Zr immunoPET agents. Zhai et al. and
Summer et al. evaluated fusarinine C, a cyclic siderophore
containing three hydroxamic acid groups, conjugated to a cy-
clic RGD peptide, and an EGFR-binding Affibody, respec-
tively [15, 35]. While only offering hexacoordination for
89Zr complexation, in vitro and in vivo results showed prom-
ising stability characteristics. Again, in their studies the
follow-up time (24 h) was too short for direct comparison of
the results with those of our study, because we observed dif-
ferences in bone uptake only beyond 72 h after injection.
Another macrocyclic hydroxamic acid-based chelator with a
hexadentate coordination was evaluated by Boros et al. [16].
Conjugated to trastuzumab, higher bone uptake was observed
in mice injected with 89Zr-labelled trastuzumab through their
newly developed chelate than labelled through DFO, indicat-
ing lower in vivo stability than DFO.Ma et al. tested a tripodal
tris(hydroxypyridinone) 89Zr chelate conjugated to
trastuzumab in vivo, but also found increased 89Zr bone
uptake in mice injected with 89Zr-labelled trastuzumab
through their new chelator compared to DFO, demonstrating
lower in vivo stability [18].
Deri et al. proposed another octadentate 89Zr chelator,
3,4,3-(LI-1,2-HOPO), consisting of four 1,2-HOPO units
(aromatic counterpart of our 1,2-PIPOH) appended to a
spermine backbone (referred to here as LI-HOPO) [19].
In vivo studies indicated that [89Zr]Zr-LI-HOPO-trastuzumab
has higher stability than [89Zr]Zr-DFO-trastuzumab, as reflected
by significantly lower bone uptake at later time points (168–
336 h after injection). However, [89Zr]Zr-DFO-trastuzumab
showed a higher tumour-to-blood uptake ratio, indicating that
the in vivo HER2-targeting properties of [89Zr]Zr-LI-HOPO-
trastuzumab may have been compromised. Another [89Zr]Zr-
HOPO-trastuzumab conjugate, incorporating 2,3-HOPO chelat-
ing groups, was described by Tinianow et al. [20], but [89Zr]Zr-
2,3-HOPO-trastuzumab did not show higher stability than
[89Zr]Zr-DFO-trastuzumab, as reflected by higher bone uptake
in animals injected with [89Zr]Zr-2,3-HOPO-trastuzumab.
Pandya et al. evaluated the use of H4DOTA as a chelator for
[89Zr]Zr4+ [24]. Despite [89Zr]Zr-DOTA showing promising
higher in vivo stability than [89Zr]Zr-DFO, DOTA may not be
a suitable chelator for use in 89Zr immunoPET, because of the
harsh labelling conditions (incubation at 95 °C for 1 h) that
would disrupt the integrity of an antibody, requiring labelling
before conjugation. Although comparing the results of the pres-
ent study with those of previous studies investigating alternative
89Zr immunoPETchelates is difficult, the present results suggest
that [89Zr]Zr4+ complexes with DFO* and DFOcyclo* show
promising in vivo stability characteristics and therefore may be
used as alternatives to DFO bioconjugates for 89Zr immunoPET,
as the latter chelator forms less-stable complexes.
The exact 89Zr release mechanism from DFO bioconju-
gates is not yet fully understood. It has been hypothesized
by Holland et al. that 89Zr-labelled metabolites enter the cir-
culation after slow intratumoral metabolism [5]. In a study
attempting to confirm this hypothesis, HER2− tumour-
Fig. 6 PET images of mice
injected with 5 MBq [89Zr]Zr-
DFO-trastuzumab, [89Zr]Zr-
DFOcyclo*-trastuzumab and
[89Zr]Zr-DFO*-trastuzumab
imaged at 168 h after injection
Eur J Nucl Med Mol Imaging (2019) 46:1966–1977 1975
bearing mice showed bone uptake after injection of 89Zr-la-
belled DFO-trastuzumab or DFOcyclo*-trastuzumab similar
to that in HER2+ tumour-bearing mice, but about 4.5 times
lower tumour uptake. This implies that with a fraction of the
tumour uptake, and consequently only a fraction of
intratumoral metabolism, 89Zr is still being released from the
DFO-trastuzumab at the same rate. We therefore hypothesize
that 89Zr is released from the chelator during physiological
metabolism and is excreted via biological pathways rather
than undergoing intratumoral metabolism.
Conclusion
The use of DFO as a chelator for 89Zr immunoPET may result
in undesired uptake of 89Zr in mineral bone. 89Zr-labelled
DFOcyclo* and DFOcyclo*-trastuzumab showed higher
in vitro and in vivo stabilities than DFO and DFO-trastuzumab.
DFOcyclo* is a highly promising candidate to become the new
clinically used standard chelator for 89Zr immunoPET.
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